A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Lola Young’s ode to finding the balance in yourself, Messy, secures a second week at Number 1 in the UK. The tune became Lola’s first UK chart-topper last week, and continues to impress as ...

“These are key risk factors for sleep apnea.” ResMed’s research – it’s now tracking 1.2 million patients – also continues to show that patients who have had a prescription for a GLP-1 drug and who ...

the analysis included 79 of these websites that sold compounded GLP-1 RAs or a prescription for compounded medications. All 79 websites sold compounded semaglutide and 72.2 and 3.8 percent sold ...

The results, out after market close yesterday evening, came more than a month after the FDA approved Eli Lilly’s GLP-1 drug Zepbound (tirzepatide) as the first and only prescription drug to ...

Novo Nordisk's product portfolio is anchored by its GLP-1 receptor agonists, which have shown strong prescription trends despite some fluctuations. As of January 2025, Ozempic's weekly ...